All In Biotech

Drug Trial Radar · NCT07685210

GenSci144 Tablets Phase I Clinical Trial

A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial in Healthy Adult Participants in China to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of GenSci144

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jun 22, 2026

Primary completion

Sep 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Jul 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a Phase I single ascending dose clinical trial in which healthy adult volunteers were administered single oral doses of GenSci144 tablets at different levels. It was conducted using a randomized, double-blind, placebo-controlled design, primarily to evaluate the drug's safety and tolerability, while also exploring its pharmacokinetic and pharmacodynamic characteristics in the body, providing a basis for subsequent clinical use in the treatment of phenylketonuria.

Conditions

  • Phenylketonuria

Interventions

  • GenSci144 tabletsDrug

    SLC6A19 transporter small molecule inhibitor, oral tablets in 25mg and 75mg, given as a single dose on an empty stomach, used to explore treatment for phenylketonuria.

  • GenSci144 placebo tabletsDrug

    No active ingredients, appearance, excipients, and specifications are exactly the same as GenSci144.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events and clinical safety indicators after a single dose.Time frame: Sign informed consent until Day3 discharge.
  2. Change in QT/QTc interval correction ΔΔQTc after dosing.Time frame: Dynamic ECG monitoring from before to 24 hours after medication.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital).

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.